In the future, the product may be used to treat melanoma
In the future, the product may be used to treat melanoma, kidney cancer, primary central nervous system tumors, and malignant solid tumors with exhausted options for standard therapy,
Coverage (4 sources)
- In Russia, preclinical studies of the oncovaccine CaTeVac have been completed — Вести
- In Russia, preclinical studies of the oncovaccine CaTeVac have been completed. Its application is proposed to begin in 2027, reported... — ТАСС (Telegram)
- Oncovaccine CaTeVac passed preclinical studies and will begin use in 2027 — Интерфакс
- Preclinical studies of the oncovaccine CaTeVac completed in Russia — Москва 24
Key entities
- Russia
- Tatyana Golikova
- Moscow
- INTERFAX.RU
- Golikova
- Federal State Budgetary Institution 'N.N. Petrov National Medical Research Center of Oncology'